Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Parramatta
Clinical trial register · Australia

Clinical Trials in Parramatta, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3343 matching records held by the registry are in this view. Synced 15 Oct 2026, 03:18 UTC
3343
Studies in scope
all four open statuses
1804
Recruiting now
open to new participants
765
Lead sponsors
across recruiting studies
Top sites
Melbourne 1096 Adelaide 565 Sydney 508 Westmead 416 Clayton 407
Narrow the registerReset
Recruitment status
Phase
Site location
Melbourne1096 Adelaide565 Sydney508 Westmead416 Clayton407
All 401 locations
Target enrolment
to

Trials with a site in Parramatta

17 of 3343 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Albury, Hurstville, Hurstville, Sydney, Launceston, Norwest, Parramatta, Strathfield, Sydney
2026-03-27
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Albury, Parramatta, Strathfield, East Melbourne
2026-03-09
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Albury, Hurstville, Parramatta, Sutherland, Sydney, East Melbourne, Rowville, Malvern
2025-11-10
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Ipswich, Maroochydore, Parramatta, South Woodville, Tiwi
2025-02-21
Active, closed
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
Albury, Hurstville, Parramatta, Sydney, Westmead, Birtinya, Adelaide
2025-02-11
Recruiting
Therini Bio Pty Ltd
Phase 1
21
Parramatta, Sydney, Westmead, Woolloongabba, Adelaide, Albans, Malvern
2024-12-20
Active, closed
Ocular Therapeutix, Inc.
Phase 3
825
Albury, Parramatta
2024-11-27
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Sydney, Albury, Parramatta
2024-08-07
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Parramatta, Heidelberg Heights
2024-06-28
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
185
Albury, Liverpool, Parramatta, Strathfield, Sydney, Adelaide, Hobart, East Melbourne
2024-01-09
Active, closed
McMaster University
Phase 4
446
Albury, Blacktown, Bondi Junction, Hurstville, Lane Cove, Liverpool, Parramatta, Strathfield
2023-05-01
Active, closed
Bristol-Myers Squibb
Phase 3
513
Liverpool, Parramatta, Maroochydore, Ivanhoe, Victoria Park
2023-01-12
Active, closed
Genentech, Inc.
Observational
400
Parramatta, Sydney, Adelaide, East Melbourne, Nedlands
2022-05-27
Active, closed
Bristol-Myers Squibb
Phase 3
338
Botany, Parramatta, Maroochydore, Woodville South, Camberwell, Geelong, Ivanhoe
2021-09-15
Active, closed
Kirby Institute
Phase 3
650
Parramatta, Sydney, Southport, Carlton, Melbourne
2021-07-08
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 October 2026. https://priyalifescience.com/clinical-trials-australia/city/parramatta

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,343 studies in total at the last sync on 15 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Parramatta.

How many clinical trials are recruiting in Parramatta?

4 of the 17 studies on this page are recruiting new participants as of the 15 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Parramatta), 17 studies
PhaseStudiesRecruitingShare
Phase 38047.1%
Phase 24223.5%
Phase 2/32111.8%
Observational105.9%
Phase 1115.9%
Phase 4105.9%

Most active sponsors

Lead sponsors with the most studies (Parramatta)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb30
EyeBiotech Ltd.21
Novartis Pharmaceuticals21
ADARx Pharmaceuticals, Inc.11
Annexon, Inc.10
Genentech, Inc.10
Janssen Research & Development, LLC10
Kirby Institute10
Kyowa Kirin Co., Ltd.10
McMaster University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.